Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3MW1

p38 kinase Crystal structure in complex with small molecule inhibitor

Summary for 3MW1
Entry DOI10.2210/pdb3mw1/pdb
Related3HRB
DescriptorMitogen-activated protein kinase 14, 8-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-2-piperidin-4-yl-1,7-naphthyridine 7-oxide (3 entities in total)
Functional Keywordsp38 map kinase, transferase, inhibitor complex, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm (By similarity): Q16539
Total number of polymer chains1
Total formula weight41698.34
Authors
Segarra, V.,Caturla, F.,Lumeras, W.,Roca, R.,Fisher, M.,Lamers, M. (deposition date: 2010-05-05, release date: 2011-04-27, Last modification date: 2023-11-01)
Primary citationLumeras, W.,Vidal, L.,Vidal, B.,Balague, C.,Orellana, A.,Maldonado, M.,Dominguez, M.,Segarra, V.,Caturla, F.
1,7-Naphthyridine 1-Oxides as Novel Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase
J.Med.Chem., 54:7899-7910, 2011
Cited by
PubMed Abstract: The design, synthesis, and ability to inhibit p38α MAP kinase by a novel series of naphthyridine N-oxides will be described. Some of these compounds showed a significant reduction in the LPS-induced TNFα production in human whole blood. Structure-activity relationship studies revealed that N-oxide oxygen was essential for activity and was probably a determinant factor for its marked selectivity against other related kinases. After an extensive SAR exercise, several compounds from this series were identified as very potent p38α inhibitors. In vivo efficacy of some derivatives was demonstrated to reduce TNFα levels in an acute murine model of inflammation (ED(50) = 0.5 mg/kg in LPS-induced TNFα production when dosed orally 1.5 h prior to LPS administration). The oral efficacy was further demonstrated in a chronic model of adjuvant arthritis in rats with established disease when administered orally (ED(50) < 1 mg/kg).
PubMed: 21999461
DOI: 10.1021/jm200975u
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

238895

건을2025-07-16부터공개중

PDB statisticsPDBj update infoContact PDBjnumon